{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T09:47:26Z","timestamp":1791798446444,"version":"4.3.4"},"reference-count":69,"publisher":"The Endocrine Society","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Despite widespread use of testosterone therapy, its efficacy and safety in men with age-related low testosterone remain a matter of debate. Elucidating its benefits and risks is essential for clinical decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence acquisition<\/jats:title>\n                    <jats:p>This narrative review synthesizes evidence from two large randomized controlled trials: the Testosterone Trials (T Trials) and the TRAVERSE trial. The T Trials assessed the efficacy of testosterone treatment in men \u226565 years with age-related syndromic androgen deficiency. The TRAVERSE trial assessed the long-term cardiovascular safety of testosterone therapy in men aged 45-80 years with high cardiovascular risk. Prostate and skeletal safety was also assessed. We critically evaluate the design, outcomes, and shortcomings of these trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence synthesis<\/jats:title>\n                    <jats:p>In the T Trials, testosterone therapy, compared with placebo, improved sexual function and mood, but not physical function, vitality, or cognitive function. In the TRAVERSE trial, testosterone therapy was noninferior to placebo with respect to major adverse cardiovascular events (MACE). Prostate-related events were comparable between groups, but fracture rates were unexpectedly higher in the testosterone group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Results from the T Trials and TRAVERSE trial showed that testosterone therapy improves sexual function and mood but not vitality or physical function. Importantly, it did not increase MACE in men at high risk of cardiovascular disease. Based on these data, treatment with testosterone could be considered in middle-aged and older men with syndromic androgen deficiency to target symptoms where it has demonstrated efficacy, whereas therapies other than testosterone might be warranted for outcomes that were not improved by testosterone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag397","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:26:23Z","timestamp":1790425583000},"source":"Crossref","is-referenced-by-count":0,"title":["Key findings on the efficacy and safety of testosterone therapy from two large randomized trials"],"prefix":"10.1210","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2996-1110","authenticated-orcid":false,"given":"Milena","family":"Braga","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1749-8549","authenticated-orcid":false,"given":"Shehzad","family":"Basaria","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"issue":"3438","key":"2026101205065509700_dgag397-B1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(00)64118-1","article-title":"Note on the effects produced on man by subcutaneous injections of a liquid obtained from the testicles of animals","volume":"134","author":"Brown-S\u00e9quard","year":"1889","journal-title":"Lancet"},{"issue":"6","key":"2026101205065509700_dgag397-B2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s11154-022-09751-8","article-title":"The medicalization of testosterone: reinventing the elixir of life","volume":"23","author":"Gagliano-Juca","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"2026101205065509700_dgag397-B3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4103\/1008-682X.122358","article-title":"Testosterone deficiency: a historical perspective","volume":"16","author":"Nieschlag","year":"2014","journal-title":"Asian J Androl"},{"issue":"2","key":"2026101205065509700_dgag397-B4","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/jcem.86.2.7219","article-title":"Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging","volume":"86","author":"Harman","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026101205065509700_dgag397-B5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1210\/jcem.87.2.8201","article-title":"Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study","volume":"87","author":"Feldman","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026101205065509700_dgag397-B6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1210\/jc.2006-1859","article-title":"The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men","volume":"92","author":"Travison","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026101205065509700_dgag397-B7","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1210\/er.2004-0013","article-title":"The decline of androgen levels in elderly men and its clinical and therapeutic implications","volume":"26","author":"Kaufman","year":"2005","journal-title":"Endocr Rev"},{"issue":"2","key":"2026101205065509700_dgag397-B8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0911101","article-title":"Identification of late-onset hypogonadism in middle-aged and elderly men","volume":"363","author":"Wu","year":"2010","journal-title":"N Engl J Med"},{"key":"2026101205065509700_dgag397-B9","author":"U.S. Food and Drug Administration"},{"key":"2026101205065509700_dgag397-B10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.coemr.2019.04.004","article-title":"Testosterone replacement in men with age-related low testosterone: what did we learn from the testosterone trials?","volume":"6","author":"Matsumoto","year":"2019","journal-title":"Curr Opin Endocr Metab Res"},{"key":"2026101205065509700_dgag397-B11","volume-title":"Testosterone and Aging: Clinical Research Directions","author":"Institute of Medicine (US) Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy","year":"2004"},{"issue":"7","key":"2026101205065509700_dgag397-B12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa1506119","article-title":"Effects of testosterone treatment in older men","volume":"374","author":"Snyder","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2026101205065509700_dgag397-B13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1000485","article-title":"Adverse events associated with testosterone administration","volume":"363","author":"Basaria","year":"2010","journal-title":"N Engl J Med"},{"issue":"17","key":"2026101205065509700_dgag397-B14","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.2013.280386","article-title":"Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels","volume":"310","author":"Vigen","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"2026101205065509700_dgag397-B15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085805","article-title":"Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men","volume":"9","author":"Finkle","year":"2014","journal-title":"PLoS One"},{"key":"2026101205065509700_dgag397-B16","article-title":"Testosterone treatment and risk of venous thromboembolism: population based case-control study","volume":"355","author":"Martinez","year":"2016","journal-title":"BMJ"},{"issue":"2","key":"2026101205065509700_dgag397-B17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2215025","article-title":"Cardiovascular safety of testosterone-replacement therapy","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026101205065509700_dgag397-B18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ahj.2021.11.016","article-title":"Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study","volume":"245","author":"Bhasin","year":"2022","journal-title":"Am Heart J"},{"issue":"1","key":"2026101205065509700_dgag397-B19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S2213-8587(20)30367-3","article-title":"Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial","volume":"9","author":"Wittert","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2026101205065509700_dgag397-B20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1001\/jama.2015.8881","article-title":"Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial","volume":"314","author":"Basaria","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"2026101205065509700_dgag397-B21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/00926239708403933","article-title":"The Derogatis Interview for Sexual Functioning (DISF\/DISF-SR): an introductory report","volume":"23","author":"Derogatis","year":"1997","journal-title":"J Sex Marital Ther"},{"issue":"7","key":"2026101205065509700_dgag397-B22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jama.2016.21044","article-title":"Testosterone treatment and cognitive function in older men with low testosterone and age-associated memory impairment","volume":"317","author":"Resnick","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"2026101205065509700_dgag397-B23","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamainternmed.2016.9539","article-title":"Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial","volume":"177","author":"Snyder","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"4","key":"2026101205065509700_dgag397-B24","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jamainternmed.2016.9540","article-title":"Association of testosterone levels with anemia in older men: a controlled clinical trial","volume":"177","author":"Roy","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"9","key":"2026101205065509700_dgag397-B25","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/gerona\/glv031","article-title":"Recruitment and screening for the testosterone trials","volume":"70","author":"Cauley","year":"2015","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"4","key":"2026101205065509700_dgag397-B26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/sj.ijir.3900857","article-title":"The International Index of Erectile Function (IIEF): a state-of-the-science review","volume":"14","author":"Rosen","year":"2002","journal-title":"Int J Impot Res"},{"issue":"20","key":"2026101205065509700_dgag397-B27","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJM199805143382001","article-title":"Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group","volume":"338","author":"Goldstein","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"2026101205065509700_dgag397-B28","article-title":"Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"2026101205065509700_dgag397-B29","doi-asserted-by":"crossref","first-page":"639","DOI":"10.7326\/0003-4819-151-9-200911030-00151","article-title":"Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians","volume":"151","author":"Qaseem","year":"2009","journal-title":"Ann Intern Med"},{"issue":"9","key":"2026101205065509700_dgag397-B30","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7326\/0003-4819-151-9-200911030-00150","article-title":"Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis","volume":"151","author":"Tsertsvadze","year":"2009","journal-title":"Ann Intern Med"},{"issue":"3","key":"2026101205065509700_dgag397-B31","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1073\/pnas.97.3.1202","article-title":"Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides","volume":"97","author":"Gouras","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2026101205065509700_dgag397-B32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2265.2009.03692.x","article-title":"Association between sex steroids and cognition in elderly men","volume":"72","author":"LeBlanc","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2026101205065509700_dgag397-B33","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1210\/jc.2002-020419","article-title":"Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men","volume":"87","author":"Moffat","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026101205065509700_dgag397-B34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1037\/0735-7044.108.2.325","article-title":"Testosterone influences spatial cognition in older men","volume":"108","author":"Janowsky","year":"1994","journal-title":"Behav Neurosci"},{"issue":"8","key":"2026101205065509700_dgag397-B35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S2213-8587(16)30102-4","article-title":"Effects of long-term testosterone administration on cognition in older men with low or low-to-normal testosterone concentrations: a prespecified secondary analysis of data from the randomised, double-blind, placebo-controlled TEAAM trial","volume":"4","author":"Huang","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2026101205065509700_dgag397-B36","first-page":"4358","article-title":"Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism","volume":"81","author":"Katznelson","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026101205065509700_dgag397-B37","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1210\/jcem.82.8.4163","article-title":"Long-term effect of testosterone therapy on bone mineral density in hypogonadal men","volume":"82","author":"Behre","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026101205065509700_dgag397-B38","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s11154-022-09738-5","article-title":"Bone health in ageing men","volume":"23","author":"David","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"issue":"7","key":"2026101205065509700_dgag397-B39","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-110-7-526","article-title":"Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism","volume":"110","author":"Greenspan","year":"1989","journal-title":"Ann Intern Med"},{"issue":"9","key":"2026101205065509700_dgag397-B40","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s40520-023-02478-9","article-title":"Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis","volume":"35","author":"Beaudart","year":"2023","journal-title":"Aging Clin Exp Res"},{"issue":"12","key":"2026101205065509700_dgag397-B41","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/jbmr.4719","article-title":"The efficacy and safety of abaloparatide-SC in men with osteoporosis: a randomized clinical trial","volume":"37","author":"Czerwinski","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2026101205065509700_dgag397-B42","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1210\/jc.2014-4079","article-title":"A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial","volume":"100","author":"Langdahl","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"2026101205065509700_dgag397-B43","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2026101205065509700_dgag397-B44","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/M16-2577","article-title":"Bone health and bone-targeted therapies for nonmetastatic prostate cancer: a systematic review and meta-analysis","volume":"167","author":"Alibhai","year":"2017","journal-title":"Ann Intern Med"},{"issue":"8","key":"2026101205065509700_dgag397-B45","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"2026101205065509700_dgag397-B46","first-page":"1966","article-title":"Effect of testosterone treatment on bone mineral density in men over 65 years of age","volume":"84","author":"Snyder","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026101205065509700_dgag397-B47","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2011-3045","article-title":"Osteoporosis in men: an Endocrine Society clinical practice guideline","volume":"97","author":"Watts","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026101205065509700_dgag397-B48","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/BF03345745","article-title":"Androgens and erythropoiesis: past and present","volume":"32","author":"Shahani","year":"2009","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2026101205065509700_dgag397-B49","doi-asserted-by":"crossref","first-page":"E1185","DOI":"10.1152\/ajpendo.00272.2018","article-title":"Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer","volume":"315","author":"Gagliano-Juca","year":"2018","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"7","key":"2026101205065509700_dgag397-B50","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nrendo.2013.73","article-title":"Risks and benefits of testosterone therapy in older men","volume":"9","author":"Spitzer","year":"2013","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2026101205065509700_dgag397-B51","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1182\/blood-2017-07-746446","article-title":"Anemia at older age: etiologies, clinical implications, and management","volume":"131","author":"Stauder","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2026101205065509700_dgag397-B52","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1741-7015-11-108","article-title":"Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials","volume":"11","author":"Xu","year":"2013","journal-title":"BMC Med"},{"issue":"5","key":"2026101205065509700_dgag397-B53","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/14740338.2024.2337741","article-title":"Cardiovascular safety of testosterone replacement therapy in men: an updated systematic review and meta-analysis","volume":"23","author":"Corona","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"2026101205065509700_dgag397-B54","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1210\/jc.2009-2575","article-title":"Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis","volume":"95","author":"Fernandez-Balsells","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"40","key":"2026101205065509700_dgag397-B55","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1093\/eurheartj\/ehv346","article-title":"Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men","volume":"36","author":"Sharma","year":"2015","journal-title":"Eur Heart J"},{"issue":"6","key":"2026101205065509700_dgag397-B56","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1530\/EJE-13-0321","article-title":"Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes","volume":"169","author":"Muraleedharan","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026101205065509700_dgag397-B57","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-6196(11)60964-6","article-title":"Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"82","author":"Haddad","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2026101205065509700_dgag397-B58","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa2308836","article-title":"Testosterone treatment and fractures in men with hypogonadism","volume":"390","author":"Snyder","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"2026101205065509700_dgag397-B59","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.48692","article-title":"Prostate safety events during testosterone replacement therapy in men with hypogonadism: a randomized clinical trial","volume":"6","author":"Bhasin","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2026101205065509700_dgag397-B60","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"issue":"9","key":"2026101205065509700_dgag397-B61","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1002\/oby.23842","article-title":"Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity","volume":"31","author":"Wilkinson","year":"2023","journal-title":"Obesity (Silver Spring)"},{"issue":"10","key":"2026101205065509700_dgag397-B62","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"2026101205065509700_dgag397-B63","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med"},{"issue":"14","key":"2026101205065509700_dgag397-B64","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2026101205065509700_dgag397-B65","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1210\/jc.2017-02243","article-title":"The effect of testosterone on cardiovascular biomarkers in the testosterone trials","volume":"103","author":"Mohler","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026101205065509700_dgag397-B66","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamainternmed.2023.7862","article-title":"Effect of testosterone on progression from prediabetes to diabetes in men with hypogonadism: a substudy of the TRAVERSE randomized clinical trial","volume":"184","author":"Bhasin","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"1","key":"2026101205065509700_dgag397-B67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-025-04124-5","article-title":"The expanding landscape of GLP-1 medicines","volume":"32","author":"Drucker","year":"2026","journal-title":"Nat Med"},{"issue":"2","key":"2026101205065509700_dgag397-B68","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.cmet.2023.12.018","article-title":"Prevention of cardiorenal complications in people with type 2 diabetes and obesity","volume":"36","author":"Drucker","year":"2024","journal-title":"Cell Metab"},{"issue":"10296","key":"2026101205065509700_dgag397-B69","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag397\/71403474\/dgag397.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag397\/71403474\/dgag397.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T09:07:12Z","timestamp":1791796032000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article\/doi\/10.1210\/clinem\/dgag397\/8836691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":69,"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag397","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"article-number":"dgag397"}}